AVEO missed earnings - kidney cancer treatment too thinly traded
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
評論:
Currently at 618fibretracement
評論:
Full 241% retracement and bounce to 161%. Sign of bouncing cat?